Patel, Tirth K.
Habimana-Griffin, LeMoyne
Gao, Xuefeng
Xu, Baogang
Achilefu, Samuel
Alitalo, Kari
McKee, Celia A.
Sheehan, Patrick W.
Musiek, Erik S.
Xiong, Chengjie
Coble, Dean
Holtzman, David M. http://orcid.org/0000-0002-3400-0856
Funding for this research was provided by:
National Institutes of Health (NS090934, AG04867801, S10OD020129)
Article History
Received: 26 November 2018
Accepted: 20 February 2019
First Online: 27 February 2019
Ethics approval and consent to participate
: Animal husbandry, housing and all procedures were performed following protocols approved by the Animal Studies Committee and Washington University School of Medicine.
: Not applicable.
: DMH is listed as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. DMH co-founded and is on the scientific advisory board of C2N Diagnostics, LLC. C2N Diagnostics, LLC has licensed certain anti-tau antibodies to AbbVie for therapeutic development. DMH is on the scientific advisory board of Proclara and Denali and consults for Genentech and AbbVie.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.